Condition: Type 2 Diabetes Mellitus in Obese · Heart Failure With Preserved Ejection Fraction · Sponsor: The University of Texas Health Science Center at San Antonio
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
This description comes directly from the study's public registry record.
Sivaram Neppala, MD · 210-358-7200 · neppalas@uthscsa.edu
Andrea Hansis-Diarte, MPH · 210-567-3208 · Hansisdiarte@uthscsa.edu
Always discuss trial participation with your own doctor first.
| Texas Diabetes Institute/UH | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05838287